this is the first report of interaction between terfenadine and itraconazole.
A 26 year old woman had been taking terfenadine 60mg twice daily for eight days for relapsing sinusitis when she began taking itraconazole 100mg twice daily for vaginitis. On the third evening of the concomitant medication she started to have syncopal episodes. On admission to hospital next morning her electrocardiogram showed a QT-interval of 580 ms at a heart rate of 67 beats/min. Several bursts of torsades de pointes ventricular tachycardia were documented, two of them associated with syncope. Serum electrolyte concentrations were normal. Terfenadine and itraconazole were discontinued and propranolol started. She was also taking oral contraceptives, which were not stopped. No more arrhythmias were seen 20 hours after the last terfenadine tablet. The QTinterval gradually returned to normal within three days.
The patient was small (152 cm, 44 kg), and physical examination revealed no abnormal findings. Liver function values were normal. The electrocardiograms of her family members exhibited normal QTintervals. Exercise test, echocardiogram, 24 hour ambulatory electrocardiographic monitoring, antimyosin scanning, and electrophysiological testing all gave normal results. Propranolol was discontinued.
Five serum samples, taking 19-84 hours after the last dose of terfenadine, consistently showed impaired metabolism of terfenadine. Unmetabolised terfenadine is normally undetectable-that is <10,I g/l in plasma, but it was detected up to 60 hours (12 ,ug/l) after the last tablet of terfenadine. The first serum sample contained 28 ,ug/l. This 58 year old woman had an unremarkable history until 1991, when she began complaining of arthralgias, occasionally treated with a pyrazolone derivative without any untoward effect. In March 1992, after three months without treatment, ketorolac trometamol 10 mg twice a day was prescribed for recurrent arthralgia. Treatment was discontinued after a total dose of 30mg because of vomiting and bloody diarrhoea and she was admitted to our department the next day. On admission she had apparently already recovered, physical examination was negative, and routine laboratory values were all normal. She did well until the third day, when she again suffered nausea and vomiting. Oliguria, facial and peripheral oedema, and hypertension also appeared. Haemolytic anaemia (haemoglobin 90g/1, packed cell volume 25%, unconjugated nitrogen 24 mmol/l, creatinine 250 ,umoIl/) with mild proteinuria (2-89 g/24 h) were detected. Coombs test was negative and no red cell enzyme deficiencies were detected. The laboratory and clinical picture of microangiopathic anaemia was confirmed by the presence of schistocytes on peripheral blood smears. Frusemide and non-specific supportive care were administered and the patient rapidly recovered. All laboratory values were back to normal in eight days. Neither malignancy nor infection could be recognised and no drug other than ketorolac had been given. Ketorolac was therefore probably responsible for the syndrome. To our knowledge only one case of drug induced haemolytic-uraemic syndrome has been reported among non-steroidal anti-inflammatory drugs,5 and this is the first one attributable to ketorolac.
